Clinical Trial ResultsAlterity Therapeutics reported positive clinical results for its Phase 2 trial of ATH434 in Multiple System Atrophy (MSA), including 48% slowing of clinical progression at the 50 mg dose level and 29% slowing at the larger 75 mg dose after 52 weeks when compared to placebo.
Financial PositionAlterity announced it raised A$40M (~$24.8M in USD) through a two-tranche placement of its fully paid ordinary shares, which could extend the cash runway through CY26.
Regulatory EngagementBased on the Phase 2 results, Alterity intends to engage the FDA to discuss next steps in the development of ATH434 in MSA, a disease with a small patient population but few treatment options at the present time.